Диссертация (1091769), страница 25
Текст из файла (страница 25)
Williams // CRC Press. — 1993. — P. 374.110) Peter, A.S Liquid chromatography studies on the enzymatic degradation ofluteinizing hormone-releasing hormone analogues with off-line identification by massspectrometry [Text] / A.S. Peter, S. Devadder, G. Laus, D. Tourwe // J. Chromatogr. A.— 1996. — Vol. 729.
— No 1—2. — P. 137—142.111) Zhong, X. Biological insights into therapeutic protein modificationsthroughout trafficking and their biopharmaceutical applications [Text] / X. Zhong, J.F.Wright // Int. J. Cell Biol. 2013. — Vol. 2013. — No 273086.148112) Prigge, S.T. New insights into copper monooxygenases and peptideamidation: structure, mechanism and function [Text] / S.T.
Prigge, R.E. Mains, B.A.Eipper, L.M. Amzel // Cell. Mol. Life Sci. — 2000. — Vol. 57. — No 12. — P. 1236—1259.113) Hruby, V.J. Design of peptide and peptidomimetic ligands with novelpharmacological activity profiles [Text] / V.J. Hruby, M. Cai // Annu. Rev. Pharmacol.Toxicol. — 2013. — Vol. 53. — No 8—9. — P. 557—580.114) Jones, D.A. Characterization of the deamidase enzyme responsible for themetabolism of the anticancer peptide: H-Arg-D-Trp-NmePhe-D-Trp-Leu-Met-NH2[Text] / D.A. Jones, J. Cummings, S.P.
Langdon, A. MacLellan, J.F. Smyth // Biochem.Pharmacol. — 1995. — Vol. 50. — No 5. — P. 585—590.115) Jones, D.A. Metabolism of the broad-spectrum neuropeptide growth factorantagonist: [D-Arg1, D-Phe5, D-Trp7,9, Leu11]-substance P [Text] / D.A. Jones, J.Cummings, S.P. Langdon, A.J. Maclellan, T. Higgins, E. Rozengurt, J.F. Smyth // Br. J.Cancer. — 1996. — Vol.
73. — No 6. — P. 715—720.116) Thomas, A. Metabolism of growth hormone releasing peptides [Text] / A.Thomas, P. Delahaut, O. Krug, W. Schänzer, M. Thevis // Anal. Chem. — 2012. —Vol. 84. — No 23. — P. 10252—10259.117) Esposito, S. In vitro models for metabolic studies of small peptidehormones in sport drug testing [Text] / S. Esposito, K. Deventer, L. Geldof, P.
VanEenoo // J. Pept. Sci. — 2015. — Vol. 21. — No 1. — P. 1—9.118) Rink, R. To protect peptide pharmaceuticals against peptidases [Text] / R.Rink, K.A. Arkema-Meter, I. Baudoin, E. Post, A. Kuipers, S.A. Nelemans, M.H.Akanbi, G.N. Moll // J. Pharmacol. Toxicol. Methods. — 2010. — Vol. 61. — No 2.
—P. 210—218.119) Nestor, J.J. The medicinal chemistry of peptides [Text] / J.J. Nestor // Curr.Med. Chem. — 2009. — Vol. 16. — No 33. — P. 4399—4418.120) Dennis, M.S. Albumin binding as a general strategy for improving thepharmacokinetics of proteins [Text] / M.S. Dennis, M. Zhang, Y.G. Meng, M.149Kadkhodayan, D. Kirchhofer, D. Combs, L.A. Damico // J. Biol. Chem. — 2002.
—Vol. 277. — No 38. — P. 35035—35043.121) Kwok, W.H. Doping control analysis of seven bioactive peptides in horseplasma by liquid chromatography-mass spectrometry [Text] / W.H. Kwok, E.N.M. Ho,M.Y. Lau, G.N.W. Leung, A.S.Y. Wong, T.S.M. Wan // Anal. Bioanal. Chem. — 2013.— Vol. 405. — No 8. — P. 2595—2606.122) Ho, E.N.M. Doping control analysis of TB-500, a synthetic version of anactive region of thymosin β4, in equine urine and plasma by liquid chromatographymass spectrometry [Text] / E.N.M. Ho, W.H. Kwok, M.Y. Lau, A.S.Y.
Wong, T.S.M.Wan, K.K.H. Lam, P.J. Schiff, B.D. Stewart // J. Chromatogr. A. — 2012. —Vol. 1265. — No 12. — P. 57—69.123) Lim, S.I. Site-specific fatty acid-conjugation to prolong protein half-life invivo [Text] / S.I. Lim, Y. Mizuta, A. Takasu, Y.S. Hahn, Y.H. Kim, I. Kwon // J.Control. Release. — 2013. — Vol. 170.
— No 2. — P. 219—225.124) Scarth, J.P. The use of in vitro technologies coupled with high resolutionaccurate mass LC-MS for studying drug metabolism in equine drug surveillance [Text] /J.P. Scarth, H.A. Spencer, S.E. Timbers, S.C. Hudson, L.L. Hillyer // Drug Test. Anal.— 2010. — Vol. 2. — No 1. — P.
1—10.125) Fenwick, S.J. In vitro metabolism of tiletamine, zolazepam andnonbenzodiazepine sedatives: Identification of target metabolites for equine dopingcontrol [Text] / S.J. Fenwick, J.P. Scarth // Drug Test. Anal. — 2011. — Vol. 3. —No 10. — P. 705—716.126) Wilk-Zasadna, I. Biotransformation in vitro: An essential consideration inthe quantitative in vitro-to-in vivo extrapolation (QIVIVE) of toxicity data [Text] / I.Wilk-Zasadna, C. Bernasconi, O. Pelkonen, S. Coecke // Toxicology. — 2015. —Vol. 332. — P. 8—19.127) Wrighton, S.A. The Use of in vitro metabolism techniques in the planningand interpretation of drug safety studies [Text] / S.A.
Wrighton, B.J. Ring, M.Vandenbranden // Toxicol. Pathol. — 1995. — Vol. 23. — No 2. — P. 199—208.150128) Fasinu, P. Liver-based in vitro technologies for drug biotransformationstudies - a review [Text] / P. Fasinu, P.J. Bouic, B. Rosenkranz // Curr. Drug Metab. —2012. — Vol. 13. — No 2. — P. 215—224.129) Zhang, D. Preclinical experimental models of drug metabolism anddisposition in drug discovery and development [Text] / D. Zhang, G. Luo, X. Ding, C.Lu // Acta Pharm. Sin.
B. — 2012. — Vol. 2. — No 6. — P. 549—561.130) Liu, X. The conduct of drug metabolism studies considered good practice(I): analytical systems and in vivo studies [Text] / X. Liu, L. Jia // Curr. Drug Metab. —2007. — Vol. 8. — No 8. — P. 815—821.131) Mire-Sluis, A.R. Progress in the use of biological assays during thedevelopment of biotechnology products [Text] / A.R. Mire-Sluis // Pharm.
Res. —2001. — Vol. 18. — No 9. — P. 1239—1246.132) Tang, L. Pharmacokinetic aspects of biotechnology product [Text] / L.Tang, A.M. Persky, G. Hochhaus, B. Meibohm // J. Pharm. Sci. — 2004. — Vol. 93. —No 9. — P. 2184—2204.133) Christin-Maitre, S. Bioassays of gonadotropins [Text] / S. Christin-Maitre,C.
Vasseur, B. Fauser, P. Bouchard // Methods. — 2000. — Vol. 21. — No 1. —P. 51—57.134) Tyrkko, E. In silico methods in prediction of drug metabolism, massfragmentation, and chromatographic behavior : application to toxicological drugscreening by liquid chromatography/time-of-flight mass spectrometry [Text] / E.Tyrkko // Rapid Commun.
Mass Spectrom. — 2009. — Vol. 23. — No 4. — P. 506—514.135) Shityakov, S. In silico, in vitro and in vivo methods to analyse drugpermeation across the blood-brain barrier: A critical review. [Text] / S. Shityakov, E.Salvador, C. Forster // OA Anaesthetics. — 2013. — Vol. 1. — No 2. — P.
13.136) Czodrowski, P. Computational approaches to predict drug metabolism[Text] / P. Czodrowski, J.M. Kriegl, S. Scheuerer, T. Fox // Expert Opin. Drug Metab.Toxicol. — 2009. — Vol. 5. — No 1. — P. 15—27.151137) Wishart, D.S. Improving early drug discovery through ADME modelling[Text] / D.S.
Wishart // Drugs. — 2007. — Vol. 8. — No 6. — P. 349—362.138) Ekins, S. In silico pharmacology for drug discovery: applications to targetsand beyond [Text] / S. Ekins, J. Mestres, B. Testa // Br. J. Pharmacol. — 2007. —Vol. 152. — No 1. — P. 21—37.139) Prakash, C. Analytical strategies for identifying drug metabolites [Text] /C. Prakash, C.L. Shaffer, A. Nedderman // Mass Spectrom.
Rev. — 2007. — Vol. 26.— No 3. — P. 340—369.140) Willette, R.E. Development of assays for drugs of abuse [Text] / R.E.Willette // Control. Clin. Trials. — 1984. — Vol. 5. — No 4 (Suppl). — P. 466—471.141) Toon, S. The relevance of pharmacokinetics in the development ofbiotechnology products [Text] / S. Toon // Eur. J.
Drug Metab. Pharmacokinet. — 1996.— Vol. 21. — No 2. — P. 93—103.142) Lim, H.K. A nonradioactive approach to investigate the metabolism oftherapeutic peptides by tagging with127I and using inductively-coupled plasma massspectrometry analysis [Text] / H.K. Lim, Y. Cao, X. Qiu, J. Silva, D.C. Evans // DrugMetab. Dispos. — 2015. — Vol. 43.
— No 1. — P. 17—26.143) Katsila, T. Peptide and protein drugs: the study of their metabolism andcatabolism by mass spectrometry [Text] / T. Katsila, A.P. Siskos, C. Tamvakopoulos //Mass Spectrom. Rev. — 2012. — Vol. 31. — No 1. — P. 110—133.144) Whitehouse, C.M.
Electrospray interface for liquid chromatographs andmass spectrometers [Text] / C.M. Whitehouse, R.N. Dreyer, M. Yamashita, J.B. Fenn //Anal. Chem. — 1985. — Vol. 57. — No 3. — P. 675—679.145) Horning, E.C. Atmospheric pressure ionization (API) mass spectrometry.Solvent-mediated ionization of samples introduced in solution and in a liquidchromatograph effluent stream [Text] / E.C.
Horning, D.I. Carroll, I. Dzidic, K.D.Haegele, M.G. Horning, R.N. Stillwell // J. Chromatogr. Sci. — 1974. — Vol. 11. —No 12. — P. 725—729.152146) Tanaka, K. The origin of macromolecule ionization by laser irradiation(Nobel lecture) [Text] / K. Tanaka // Angew. Chem.
Int. Ed. Engl. — 2003. — Vol. 42.— No 33. — P. 3860—3870.147) Okano, M. Determination of growth hormone secretagogue pralmorelin(GHRP-2) and its metabolite in human urine by liquid chromatography/electrosprayionization tandem mass spectrometry [Text] / M. Okano, M. Sato, A. Ikekita, S.Kageyama // Rapid Commun. Mass Spectrom. — 2010. — Vol. 24. — No 14.
—P. 2046—2056.148) Thomas, A. Comprehensive plasma-screening for known and unknownsubstances in doping controls [Text] / A. Thomas, S. Guddat, M. Kohler, O. Krug, W.Schanzer, M. Petrou, M. Thevis // Rapid Commun. Mass Spectrom.
— 2010. —Vol. 24. — No 8. — P. 1124—1132.149) Thomas, A. Determination of prohibited, small peptides in urine for sportsdrug testing by means of nano-liquid chromatography/benchtop quadrupole orbitraptandem-mass spectrometry [Text] / A. Thomas, K. Walpurgis, O.
Krug, W. Schanzer,M. Thevis // J. Chromatogr. A. — 2012. — Vol. 1259. — P. 251—257.150) Gil, J. Development and validation of a bioanalytical LC–MS method forthe quantification of GHRP-6 in human plasma [Text] / J. Gil, A. Cabrales, O.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
